FDA generics chief moves to new agency job; Allergan under seige;

     @FiercePharma: Pfizer chief gets 12.8% salary hike. Report | Follow @FiercePharma

> FDA's director of generics Gary Buehler is taking another post at the agency in its Office of Pharmaceutical Science, with that office's deputy to take Buehler's job temporarily. Report

> Allergan is under siege from prosecutors, according to its annual report, and may burn nearly $100 million in legal fees defending its Botox marketing against the government. Report

> Merck and its Schering unit are suing Teva Pharmaceutical Industries Ltd. to prevent it from selling a generic version of the cholesterol drug Vytorin in the U.S. until 2017. Report

> Baxter International sold $600 million of senior notes in two parts, with Credit Suisse, Deutsche Bank and Goldman Sachs serving as joint bookrunning managers for the sale. Report

> The chairman of German drug and chemical giant Merck KGaA said he plans to move the U.S. chemicals headquarters to Billerica, Mass., from New Jersey. Report

Biotech News

  Sanofi offers promising survival data on prostate cancer drug cabazitaxel. Article  | Follow @FierceBiotech

 Yesterday I calculated that I have written more than two million words on biotech. There has to be a cure.... Follow @JohnCFierce

> Just 16 months after raising $20 million in its first round of funding, Massachusetts-based Alnara Pharmaceuticals says it's preparing an NDA for its cystic fibrosis treatment. Story

> Chinese drugmaker could partner with Abbott. Report

> InterMune gears up for panel review. Item

> Apixaban superior to Lovenox in study. Article

> Resverlogix looks to succeed where Pfizer failed. Story

And Finally... How was a cancer patient charged $27,360 for each of four Avastin treatments that should have cost less than one-fourth that much? Report